Windlas Biotech Ltd

Windlas Biotech Ltd has seen a notable change in its valuation parameters, moving from an attractive to a fair rating as of mid-2026. This shift reflects evolving market perceptions amid a competitive pharmaceuticals and biotechnology sector, where peers continue to command premium multiples. Investors are advised to consider these valuation dynamics alongside the company’s operational metrics and broader market trends.

Windlas Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 27 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 15 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite some lingering concerns over flat quarterly performance and modest long-term growth. The company’s current Mojo Score stands at 58.0, signalling a cautious but more optimistic outlook for investors.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underscored by a combination of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a cautious but improving trend for the pharmaceutical and biotechnology small-cap stock.

The 50-day moving average has crossed above the 200-day moving average for Windlas Biotech Ltd, signalling a golden cross on 15 Jul 2026. Yet, the stock declined 1.42% on the day the cross formed, while monthly technical indicators remain mildly bearish. This juxtaposition of signals calls for a detailed examination of the broader technical and fundamental context.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Windlas Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a recent downgrade in its overall Mojo Grade to Sell. This recalibration in price-to-earnings and price-to-book value metrics, when analysed against historical trends and peer benchmarks, suggests a nuanced investment opportunity within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from fair to attractive territory despite ongoing sector headwinds. With a current price of ₹791.95 and a market cap categorised as small-cap, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.